Regeneron's BCMAxCD3 Bispecific Antibody (REGN5458) Shows Deep and Durable Responses in Patients with Heavily-pretreated Multiple Myeloma in Phase 1

TARRYTOWN, N.Y., Dec. 5, 2020 /PRNewswire/ -- 63% response rate in patients treated with the highest reported doseAmong all patients responding to treatment, 95% experienced a very good partial response or better; among responding patients witha??6 months of follow-up, 83% have ongoing responses for up to 13 months at the time of analysis Potentially registrational Phase 2 portion of the trial has been initiated and is enrolling patients Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced updated data for REGN5458, a BCMAxCD3 bispecific antibody, from the Phase 1 portion of a Phase 1/2 trial in patients withA relapsed or refractory (R/R) multiple myeloma. The results were shared in an oral presentation at the virtual 2020 American Society of Hematology (ASH) Annual Meeting. BCMA (B-cell maturation antigen) is a protein that is typically over-expressed on multiple myeloma cells. REGN5458 is designed to bind to BCMA on multiple myeloma cells and the CD3 receptor on T-cells in order to bridge them together and activate T-cells to kill the cancer cells.
See also:
Leave a comment
  • Latest
  • Read
  • Commented
Calendar Content
«    Январь 2021    »